Literature DB >> 17192931

MGMT methylation: a marker of response to temozolomide in low-grade gliomas.

Sibille Everhard1, Gentian Kaloshi, Emmanuelle Crinière, Alexandra Benouaich-Amiel, Julie Lejeune, Yannick Marie, Marc Sanson, Michèle Kujas, Karima Mokhtari, Khê Hoang-Xuan, Jean-Yves Delattre, Joëlle Thillet.   

Abstract

The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression-free survival as compared with unmethylated MGMTP tumors (p < 0.0001). Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17192931     DOI： 10.1002/ana.21044

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  64 in total

1.  Oligodendrogliomas: a short history of clinical developments.

Authors:  Martin J van den Bent
Journal:  CNS Oncol       Date:  2015

2.  Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.

Authors:  Agustí Alentorn; Hinke F van Thuijl; Yannick Marie; Hussa Alshehhi; Catherine Carpentier; Blandine Boisselier; Florence Laigle-Donadey; Karima Mokhtari; Ilari Scheinin; Pieter Wesseling; Bauke Ylstra; Laurent Capelle; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Jaap C Reijneveld; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300

3.  Adult brainstem gliomas: Correlation of clinical and molecular features.

Authors:  Brett J Theeler; Benjamin Ellezam; Isaac Melguizo-Gavilanes; John F de Groot; Anita Mahajan; Kenneth D Aldape; Janet M Bruner; Vinay K Puduvalli
Journal:  J Neurol Sci       Date:  2015-04-18       Impact factor: 3.181

Review 4.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

Review 5.  Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.

Authors:  Yanxin Lu; Yang Liu; Ying Pang; Karel Pacak; Chunzhang Yang
Journal:  Pharmacol Ther       Date:  2018-04-03       Impact factor: 12.310

Review 6.  Molecular epigenetics and genetics in neuro-oncology.

Authors:  Raman P Nagarajan; Joseph F Costello
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

7.  Upfront chemotherapy and subsequent resection for molecularly defined gliomas.

Authors:  Hikaru Sasaki; Yuichi Hirose; Takahito Yazaki; Yohei Kitamura; Makoto Katayama; Tokuhiro Kimura; Hirokazu Fujiwara; Masahiro Toda; Takayuki Ohira; Kazunari Yoshida
Journal:  J Neurooncol       Date:  2015-05-26       Impact factor: 4.130

8.  An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas.

Authors:  Jingtao Wang; Xuejun Zheng; Jinling Zhang; Hao Xue; Lijie Wang; Rui Jing; Shuo Chen; Fengyuan Che; Xueyuan Heng; Gang Li; Fuzhong Xue
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

9.  Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.

Authors:  Andrew L Lin; Jingxia Liu; John Evans; Eric C Leuthardt; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Albert H Kim; Gregory J Zipfel; Robert L Grubb; Jiayi Huang; Clifford G Robinson; Joseph R Simpson; Gerald P Linette; Michael R Chicoine; David D Tran
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

Review 10.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.